TWI342778B - Therapeutic agent for fibromyalgia - Google Patents
Therapeutic agent for fibromyalgia Download PDFInfo
- Publication number
- TWI342778B TWI342778B TW092130544A TW92130544A TWI342778B TW I342778 B TWI342778 B TW I342778B TW 092130544 A TW092130544 A TW 092130544A TW 92130544 A TW92130544 A TW 92130544A TW I342778 B TWI342778 B TW I342778B
- Authority
- TW
- Taiwan
- Prior art keywords
- agent
- therapeutic agent
- fibromyalgia
- improvement
- vaccinia virus
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 50
- 208000001640 Fibromyalgia Diseases 0.000 title claims description 45
- 229940124597 therapeutic agent Drugs 0.000 title claims description 44
- 210000001519 tissue Anatomy 0.000 claims description 39
- 241000700618 Vaccinia virus Species 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 239000000284 extract Substances 0.000 claims description 31
- 230000002757 inflammatory effect Effects 0.000 claims description 17
- 208000002193 Pain Diseases 0.000 claims description 15
- 230000006872 improvement Effects 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 claims description 3
- 206010038743 Restlessness Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 description 23
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010061323 Optic neuropathy Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- KSSNXJHPEFVKHY-UHFFFAOYSA-N phenol;hydrate Chemical compound O.OC1=CC=CC=C1 KSSNXJHPEFVKHY-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010068975 Bone atrophy Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- -1 or with NS A ID Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000010321 sleep therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Description
1342778 Π) 玖、發明說明 【發明所屬之技術領域】 本發明係有關牛痘苗病毒接種炎症組織萃取物之新穎 的醫藥用途者,具體而言係有關以牛痘苗病毒接種炎症組 織萃取物做爲有效成份含有之纖維肌痛症治療劑,爲製造 治療纖維肌痛症醫藥組成物之做爲有效成份之牛痘苗病毒 接種炎症組織萃取物之使用,以及投與病患以牛痘苗病毒 接種炎症組織萃取物做爲有效成份含有之醫藥組成物所成 纖維肌痛症之治療方法者。 【先前技術】 纖維肌痛症(F i b r 〇 m y a 1 g i a )係以慢性、全身性強烈 疼痛’或即使部份亦爲廣範圍之慢性疼痛爲主症狀之疾病 者’不僅肌肉組織,甚至皮膚亦出現疼痛。纖維肌痛症不 僅此全身性之慢性疼痛,多半伴隨疲勞感、倦怠感、鬱悶 、不安感、賴床感、肌肉僵硬、睡眠障礙等。且亦伴隨頭 痛、顏面痛、識別障礙(記憶錯亂、集中力不良)、胃腸 不適(內臟痛、消化系統障礙、鼓腸)頻尿、腹瀉、便秘 、月經不順等症狀。 針對美國一般人口佔纖維肌痛症發病率者女性3.4 % 、男性0.5%被報告之,大約好發於女性25〜5〇歲、病患 約8 0%爲女性,日本亦與美國差不多。纖維肌痛症其自覺 症狀爲多樣者,相反的他覺所見則特徵性全身壓痛之外不 怎麼顯現’ MRI、CT等影像檢查之外,亦檢查肌肉痛部 (2) (2)1342778 位之病理檢查,各種免疫學、病毒學、內分泌等之檢查均 無異常。如:未出現不同於類風濕性關節炎之浮腫,顯示 發炎程度之血液中指標,亦即,即使血沈,CRP於正常範 圍,病患仍有四肢、體幹廣範圍疼痛之苦。 做爲診斷方法者,目前世界性使用美國類風濕性關節 炎學會於1 990年所揭示之分類基準。此基準係以肚臍部 爲基點,上半身與下半身、右半身與左半身,甚至脊椎部 及胸骨部5處任意部位均出現疼痛,其至少持續3個月以 上時,或,所規定全身1 8處之壓痛點緩緩加重4kg,達 Π處痛覺時做爲纖維肌痛症者。 針對纖維肌痛症之發症原因,機序目前被推斷爲壓力 等心理要因、病毒感染、遺傳、免疫異常、神經傳達物質 之異常等,惟,尙未明朗。纖維肌痛症與一般生體組織之 損傷,或可能出現損傷之侵略刺激更多疼痛性疾病爲極爲 不同之疾病者,疼痛部位未出現相關病理學所見。 纖維肌痛症之治療幾乎未出現一般疼痛治療所慣用之 非類固醇性抗炎藥(NS AIDs )等消炎鎭痛劑之效果。又 ,被試用肌肉弛緩藥、非麻藥性鎭痛藥、抗不安藥等各種 藥劑,惟,其有效性之個人差極大,未出現明顯效果。因 此,目前纖維肌痛症之治療上,幾乎採用抗抑鬱藥,或此 與NS A ID之處方,對於發痛部位之局部麻醉藥、類固醇 劑之投與、按摩、運動療法、睡眠療法等。惟,所有治療 劑、方法中,其纖維肌痛症之原因不特定,治療效果亦有 極大個人差異,而無法確定治療法。 -5- (3) (3)1342778 如上述’目前尙未確定纖維肌痛症之發症原因與機序 ’未出現明顯治療效果之藥劑,而被期待開發一種安全性 高,且具效力之治療劑者。 【發明內容】 本發明者針對纖維肌痛症與診斷,於消炎鎭痛劑、抗 抑鬱藥等既存藥劑出現無效之病患,而以牛痘苗病毒接種 炎症組織萃取物做爲有效成份進行投與後結果發現,該製 劑具有明顯治療纖維肌痛症之效果。 因此,本發明係有關以牛痘苗病毒接種炎症組織萃取 物做爲有效成份含有之纖維肌痛症治療劑者。 又’本發明係有關爲製造治療纖維肌痛症醫藥組成物 之使用做爲有效成份牛痘苗病毒接種炎症組織萃取物者。 本發明更有關以牛痘苗病毒接種炎症組織萃取物做爲 有效成份含有之醫藥組成物投與病患所成之纖維肌痛症治 療方法。 【實施方式】 〔發明實施之最佳形態〕 針對病毒等由外界之侵襲、內在病態狀態之惡化,公 知者有產生防禦生物自身生體正常化之各種生體機能調整 物質者,針對牛痘苗病毒所接種之炎症組織中所產生生體 機能調整物質,由病態組織萃取該物質之製造方法及此等 藥理活性之各種報告被記載之(特公昭6 3 - 3 9 5 7 2號公報 (4) (4)1342778 、專利第2 59422 2號公報等)。 針對牛痘苗病毒接種炎症組織萃取物之藥理活性,被 揭示爲鎭痛作用、鎭靜作用、抗壓力作用、抗過敏作用( 特開昭5 3 -1 01 5 1 5號公報)、免疫促進作用、抗癌作用、 抗肝硬變作用(特開昭5 5 - 8 7 7 2 4號公報.特別爲第3、5 、6頁)、對於特發性血小板減少性紫斑病之治療效果( 特開平1 -265 02 8號公報、特別是第I、2頁)、帶狀疱疹 後神經痛、腦浮腫、痴呆、脊髓小腦變性症等之治療效果 (特開平1 -3 1 942 2號公報、特別是第3、4頁雷諾( R a y n a u d ' s )症候群、糖尿病性神經障礙< S Μ Ο N (亞急性 脊髓視神經障礙)後遺症等之治療效果(特開平2 - 2 8 Π 9 號公報、特別是第3頁)、蛋白質分解酵素產生障礙作用 ’改善末梢循環障礙作用(特開平7 - 9 7 3 3 6號公報、特別 是第4頁),改善骨萎縮作用(特開平8 - 2 9 1 0 7 7號公報 )、敗血症、內毒素之治療之有效抗一氧化氮產生之作用 (特開平1〇- 1 949·78號公報),對於骨質疏鬆症之治療效 果(特開平1 1 - 8 000 5號公報,特別是第2、3頁),抑制 Nei作用、抗Chemokain產生作用爲基礎之治療愛滋效果 (特開平U -丨3997 7號公報、及特開2000-336034號公報 ,等’第2、3頁) > 對於腦梗塞等缺血性疾病之治療效 果(特開2000-1 6 942號公報)等,惟,有關纖維肌痛症 之治療療效之醫藥用途相關發表、報告並未出現。 牛痘苗病毒接種炎症組織萃取物係接種牛痘苗病毒於 動物後搗碎長痘組織•加入萃取溶媒去除組織片後,進行 -7 - (5) (5)1342778 除蛋白處理’吸附劑吸附此後,再溶出吸附成份後取得。 牛痘苗病毒接種炎症組織萃取物如以下步驟製造之。 (a)採取接種牛痘苗病毒長痘之兔子、老鼠等之皮 膚組織等’搗碎長痘組織後,加入水、酚水、生理食鹽水 、或苯酚加甘油水等之萃取溶媒後,藉由過濾或離心分離 後取得萃取液(濾液或上淸液)。 (b )調整該萃取液呈酸性之p Η後進行加熱,再進 行除蛋白處理。接著調整除蛋白後之溶液呈鹼性之後,加 熱之後進行過濾或離心分離。 (c )將取得濾液或上淸液做成酸性後吸附於活性碳 、陶土等吸附劑中。 (d )加入水等萃取溶媒於該吸附劑中,調整呈鹼性 pH ’藉由溶出吸附成份後,可取得牛痘苗病毒接種炎症 組織萃取物之後,於減壓下適當使溶出液藉由蒸發乾固或 凍結乾燥後亦可做成乾固物。 實際做爲醫藥品者爲牛痘苗病毒接種家兔炎症皮膚萃 取液製劑者。此製劑如醫療藥等日本醫藥品集〔2002 (第 25版)、日本醫藥情報中心編、股份公司時報發行〕之 23 79〜23 8 1頁所載,含有由接種牛痘苗病毒家兔之發炎皮 膚組織萃取分離之非蛋白性活性物質之藥劑者,被公認適 用於腰痛、頸肩腕症候群、症候性神經痛、肩關節周圍炎 、變形性關節炎、皮膚疾病(濕疹、皮膚炎、蓴麻疹)所 伴隨之搔癢、過敏性鼻炎、亞急性脊髓視神經障礙後遺症 之冷感、異常知覺、痛覺、帶狀疱疹後神經痛等,做爲皮 (6) 1342778 下、肌肉注射、靜脈注射用之注射劑及錠劑之做 醫藥品被製造市販之。 本發明纖維肌痛症治療劑之有效成份係由上 病毒接種炎症組織所萃取之非蛋白性生體機能調 ,被揭示於該醫療藥日本醫藥品集之牛痘苗病毒 炎症皮膚萃取液製劑亦以醫藥品製造被市販之。 述專利公報等文獻所記載之各種牛痘苗病毒接種 萃取物可利用於本發明,此等製造方法,理想投 於文獻說明之。 投與病患之投用方法以藉由錠劑之口服者宜 別爲症狀嚴重時,亦可使用靜脈注射、點滴注射 纖維肌痛症之症狀多樣,因此,劑型非僅限定口 服量依牛痘苗病毒接種炎症組織萃取物之種類而 之,一般其市販製劑所記載之投用量係依該醫藥 品集(2379頁)’基本上內服者爲1天16 Neurotropin)單位,注射劑爲 1日 3.6〜7.2 NU 用醫藥品之投用量’惟,可依其疾病種類、病症 病患個人差、投用方法、投與期、等而進行適當 〔實施例〕 以下顯示牛痘苗病毒接種炎症組織萃取物製 例’及新穎藥理作用’亦即纖維肌痛症相關之臨 果。又’實施例1〜3其最後步驟均施予減壓乾固 乃爲錠劑化者則將無此必要。 成醫療用 述牛痘苗 整物質者 接種家兔 又,如上 炎症組織 用量等均 ,而,特 者。由於 服者。投 適當設定 曰本醫藥 :NU )( 做爲醫療 輕重度、 曾減之。 造方法之 床試驗結 ,惟,此 -S - (7) (7)1342778 〔實施例1〕 接種牛痘苗病毒於健康成熟之家兔皮膚後,長痘後, 以無菌剝除長痘之皮膚,將此細切後,加入苯酚加甘油水 者,以勻漿器進行磨碎後,做成乳狀。再將此進行離心過 濾,取得濾液以鹽酸做成pH 4.8~5.5者,於流通蒸氣下 加熱至1 〇〇°C,進行過濾。更利用塞茨濾板過濾濾液,以 氫氧化鈉做成pH 9.2,更於100°C進行加熱後,過濾之。 使濾液以鹽酸調成pH 4.5,加入1 .5%活性碳,攪拌1~5 小時後進行過濾之。於此活性碳加水後,以氫氧化鈉調成 pH 9.4~丨0,攪拌3〜5小時後,過濾之。以鹽酸調整濾液 之pH呈7.0〜7.2,減壓下進行乾固後取得牛痘苗病毒接種 炎症組織萃取物。 〔實施例2〕 接種牛痘苗病毒於健康成熟家兔之皮膚後,剝除長痘 之皮膚,將此進行搗碎後加入酚水。再將此進行加壓過濾 ,所取得濾液以鹽酸調成pH 5,以90〜100 °C下進行加熱 處理3 0分鐘。過濾之後去除蛋白,以氫氧化鈉調成pH 爲9,更於90〜]00 °C下進行加熱處理15分鐘,過濾之。 以鹽酸調整濾液約爲pH 4.5後,加入2%活性碳攪拌2小 時,進行離心分離。於活性碳中加水,以氫氧化鈉調成 pH 10,60°C下進行攪拌1.5小時後,進行離心分離。活 性碳中加水後,以氫氧化鈉調成pH爲I 1,60°C下進行攪 -10 - 1342778
拌1 .5小時,進行離心分離。以鹽酸中和上淸液後,減壓 下乾固後取得牛豆苗病毒接種炎症組織萃取物。 〔實施例3〕 接種牛痘苗病毒於健康成熟家兔之皮膚,進行活化後 ,以無菌剝取活化皮膚,將此細切後加水,以勻漿器磨碎 ,做成乳狀物,再將此進行加壓過濾後,以鹽酸調整取得 濾液呈pH 5.0,流通蒸氣100 °C下進行加熱處理。過濾去 除蛋白後,以氫氧化鈉調成P Η 9 · 1,更於1 0 0 °C下進行加 熱處理後過濾之。以鹽酸調整濾液pH爲4.1,加入2%活 性碳攪拌2小時後,過濾之。更於濾液加入5.5 %活性碳 攪拌2小時後,過濾之。濾取最初之活性碳加入水後,以 氫氧化鈉調成pH 9.9,60°C下攪拌1.5小時後,過濾之。 於最初活性碳及下一次之活性碳中加入水後,以氫氧化鈉 調成pH爲10.9 ’ 60°C下攪拌1.5小時,過濾之。總濾液 以鹽酸中和後,以使用分子量100之膜的電氣透析法進行 脫鹽處理,減壓下乾固後取得牛豆苗病毒接種炎症組織萃 取物。 〔實施例4〕 移植L細胞(老鼠肉瘤細胞)於C3H老鼠之皮下, 】〇天後,於同部位接種牛痘苗病毒,再經過5天取出腫 瘤炎症部位。細切1 00g取出組織後,加入pH 7.0,緩衝 化之70%甘油溶液,以韋林摻混器進行磨碎後,進行3次 -11 - (9) 1342778 凍結融解操作。以2000 X g進行乳狀磨碎液之離心分離 1小時’去除沈澱後,調整上淸液p Η爲5.0,加熱至1 〇 〇 °C過濾之。調整濾液呈ρ Η 9.0,再度於1 0 0 °C下加熱,過 濾後去除不溶物。調整冷卻後濾液爲pH 4.5,通過塡充活 性碳之柱體’以蒸餾水進行洗淨後,以N / 2 5氨水進行 溶出,以鹽酸中加溶出液後取得牛痘苗病毒接種炎症組織 萃取物。
〔臨床試驗〕
依該美國類風濕性關節炎學會之分類基準,針對被診 斷爲纖維肌痛症而進行消炎鎭痛劑、抗鬱悶藥、類固醇之 局部投用等各種藥劑療法仍未見療效之8名病患,進行投 用牛痘苗病毒接種家兔炎症皮膚萃取液製劑〔製品名「 neurotropin錠」(註冊商標)〕。投用量係使含有4.0 neurotropin單位之錠劑以1天4錠,早晚投用進行2〜4 週之口服投用者,效果之判定係以投用前之疼痛爲「〗〇」 ,而針對投用後減輕程度,聽取病患之評價(VAS〔 Visual Analogue Scale〕評定)進行判定之。該臨床結果 示於表1,表2係本製劑臨床效果之整理者。 -12 - (10) 1342778 〔表1〕
No. 性別 年齡 投與前之痛感 投與後之痛感 效 果 判 定 ] 男 64 1 0 3 效 果 明 顯 2 女 62 】0 2 效 果 卓 越 3 女 67 10 8 效 果 沒 有 4 女 52 10 2 效 果 卓 越 5 女 48 10 2 效 果 卓 越 6 女 49 10 3 效 果 明 顯 7 女 69 10 8 效 果 沒 有 8 女 55 10 8 效 果 沒 有 〔表2〕 效果判定 例數(%) _ 卓效(2以下減輕者) ^ 3 ( 3 7.5%) 一 著效(3以上5以下減輕者) _ 2 ( 2 5.0%) 有效(5以上8以下減輕者) 1 0 效果沒有(8以上J____ __ 3 ( 3 7.5%) ------- 另外,該臨床試驗中出現效果之病患針對伴隨改善其 主症狀之同時亦改善疲勞感、鬱悶、不安感、賴床感、肌 肉僵硬、睡眠障礙等,明顯改善病患之Q〇l (生活品質 (11) 1342778 〔產業上可利用性〕 由上述臨床試驗結果證明,本發明牛痘苗病毒接種炎 症組織萃取物對於纖維肌痛症有顯著治療效果。特別是於 該臨床試驗開始前,使用藥劑治療仍未具改善之病患,出 現改善疾病之效果。
目前爲止,沒有比此對於纖維肌痛症更有效之藥劑, 甚至亦無取得此效能之臨床試驗之藥劑者。纖維肌痛症使 用一般非類固醇抗炎症藥(NSAIDs)等消炎鎭痛劑幾乎 無效,多半以抗鬱悶藥之處方,副作用亦頻頻出現,因此 ’被期待開發一種副作用少,且可安心使用之藥劑。本發 明藥劑係針對目前爲止仍無有效治療藥劑之纖維肌痛症的 一種新穎治療劑者,幾乎未出現副作用’且具高度安全性 之熱有效之藥劑者。 -14 -
Claims (1)
1342778 第092130544號專利申請案中文申請專利範圍修正本 〇〇年3廣: •r η曰 ϋ.日修正 民國 補充丨 拾、申請專利範圍 1 一種纖維肌痛症的改善劑或治療劑,其特徵係以含 有牛痘苗病毒接種炎症組織萃取物做爲有效成份者。 2 ·如申請專利範圍第1項之改善劑或治療劑,其中該 炎症組織爲皮膚組織者。 3 ·如申請專利範圍第1項之纖維肌痛症的改善劑或治療 劑,其係以含有牛痘苗病毒接種兔子炎症組織萃取物做爲 有效成份者。 4 ·如申請專利範圍第1項至第3項中任一項之改善劑 或治療劑,其中改善劑或治療劑爲注射劑者。 5 ·如申請專利範圍第1項至第3項中任一項之改善劑 或治療劑,其中改善劑或治療劑爲口服劑者。 6 ·如申請專利範圍第1項之纖維肌痛症的改善劑或治療 劑’其爲對纖維肌痛症的疼痛之改善劑或治療劑,以含有 牛痘苗病毒接種炎症組織萃取物做爲有效成份者。 7.如申請專利範圍第6項之改善劑或治療劑,其中該 炎症組織爲皮膚組織者。 8 ·如申請專利範圍第1項之纖維肌痛症的改善劑或治療 劑’其爲對纖維肌痛症的疼痛的改善劑或治療劑,以含有 牛痘苗病毒接種兔子炎症組織萃取物做爲有效成份者。 9.如申請專利範圍第6項至第8項中任一項之改善劑 或治療劑,其中改善劑或治療劑爲注射劑者。 1342778 1 0.如申請專利範圍第6項至第8項中任一項之改善 劑或治療劑,其中改善劑或治療劑爲口服劑者。 1 1.如申請專利範圍第1項之纖維肌痛症的改善劑或治 療劑,其爲纖維肌痛症所引起的症狀之改善劑或治療劑, 將含有牛痘苗病毒接種炎症組織萃取物做爲有效成份者。 1 2.如申請專利範圍第1 1項之改善劑或治療劑,其中 該炎症組織爲皮膚組織者。 13. 如申請專利範圍第1項之纖維肌痛症的改善劑或治 療劑,其爲纖維肌痛症所引起的症狀之改善劑或治療劑, 將含有牛痘苗病毒接種兔子炎症組織萃取物做爲有效成份者 〇 14. 如申請專利範圍第11項至第13項中任一項之改善 劑或治療劑,其中所引起的症狀爲疲勞感。 1 5 .如申請專利範圍第1 1項至第1 3項中任一項之改善 劑或治療劑,其中所引起的症狀爲倦怠感。 16.如申請專利範圍第11項至第13項中任一項之改善 劑或治療劑,其中所引起的症狀爲憂鬱。 1 7 .如申請專利範圍第1 1項至第1 3項中任一項之改善 劑或治療劑,其中所引起的症狀爲不安感。 1 8.如申請專利範圍第Π項至第1 3項中任一項之改善 劑或治療劑,其中所引起的症狀爲早晨緊張感。 19. 如申請專利範圍第11項至第13項中任一項之改善 劑或治療劑,其中所引起的症狀爲肌肉僵硬。 20. 如申請專利範圍第1 1項至第1 3項中任一項之改善 -2- 1342778 齊if或治療劑,其中所引起的症狀爲睡眠障礙。 21. 如申請專利範圍第11項至第13項中任一項之改 善劑或治療劑,其中改善劑或治療劑爲注射劑者。 22. 如申請專利範圍第1 1項至第丨3項中任一項之改 善劑或治療劑,其中改善劑或治療劑爲口服劑者。 2 3 ·如申請專利範圍第1項之纖維肌痛症的改善劑或治 療劑’其爲使用牛痘苗病毒接種炎症組織萃取物於製造纖 維肌痛症的改善劑或治療劑上。 24 ·如申請專利範圍第1項之纖維肌痛症的改善劑或治 療劑’其爲使用牛痘苗病毒接種炎症組織萃取物於製造對纖 維肌痛症的疼痛之改善劑或治療劑上。 2 5 ·如中請專利範圍第丨項之纖維肌痛症的改善劑或治 療劑,其爲使用牛痘苗病毒接種炎症組織萃取物於製造纖維 肌痛症所引起的症狀之改善劑或治療劑上。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002317011 | 2002-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW200412983A TW200412983A (en) | 2004-08-01 |
TWI342778B true TWI342778B (en) | 2011-06-01 |
Family
ID=32211708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW092130544A TWI342778B (en) | 2002-10-31 | 2003-10-31 | Therapeutic agent for fibromyalgia |
Country Status (9)
Country | Link |
---|---|
US (3) | US7148012B2 (zh) |
EP (1) | EP1566178B1 (zh) |
JP (1) | JP3887731B2 (zh) |
KR (1) | KR101097138B1 (zh) |
CN (1) | CN100464782C (zh) |
AU (1) | AU2003280684B2 (zh) |
CA (1) | CA2503810C (zh) |
TW (1) | TWI342778B (zh) |
WO (1) | WO2004039383A1 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101307999B1 (ko) | 2004-12-01 | 2013-09-12 | 니폰 조키 세야쿠 가부시키가이샤 | 건조물 및 그 제조방법 |
US20060134646A1 (en) | 2004-12-17 | 2006-06-22 | Ansari Aftab A | Method for treatment of HIV infection |
CA2600093A1 (en) * | 2005-03-07 | 2006-09-14 | St. Marianna University School Of Medicine | Proteomic methods using sart stressed animals |
TWI406664B (zh) * | 2006-03-30 | 2013-09-01 | Univ Kyoto | 硫氧還蛋白(thioredoxin)產生促進劑 |
EP2075341A4 (en) * | 2006-09-06 | 2010-09-08 | Nippon Zoki Pharmaceutical Co | METHOD FOR THE INVESTIGATION, DETERMINATION OR EVALUATION BY MEANS OF GENE EXPRESSION ANALYSIS |
WO2008029836A1 (fr) * | 2006-09-06 | 2008-03-13 | Nippon Zoki Pharmaceutical Co., Ltd. | Procédé d'étude, de détermination ou d'évaluation |
WO2008041751A1 (fr) | 2006-10-05 | 2008-04-10 | St. Marianna University School Of Medicine | Préparation pharmaceutique pour le traitement de la fibromyalgie |
WO2009025091A1 (ja) * | 2007-08-23 | 2009-02-26 | St. Marianna University School Of Medicine | 線維筋痛症治療用医薬組成物 |
US8613962B2 (en) * | 2007-08-31 | 2013-12-24 | Kyushu University, National University Corporation | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
EP2231005A1 (en) * | 2007-12-19 | 2010-09-29 | Great Lakes Biosciences, LLC | Brain-related chronic pain disorder diagnosis and assessment method |
US20090253025A1 (en) * | 2008-04-07 | 2009-10-08 | Carnegie Mellon University | Sodium ion based aqueous electrolyte electrochemical secondary energy storage device |
CA2740029C (en) * | 2008-05-16 | 2016-12-20 | Axis, Inc. | Pharmaceutical composition for treatment of fibromyalgia |
TWI483729B (zh) * | 2010-03-11 | 2015-05-11 | Nippon Zoki Pharmaceutical Co | 慢性前列腺炎、間質性膀胱炎及/或排尿障礙之改善或治療劑 |
WO2011162317A1 (ja) | 2010-06-25 | 2011-12-29 | 日本臓器製薬株式会社 | 被検物質の判定又は評価方法 |
CA2808927C (en) | 2010-10-14 | 2018-10-30 | Nippon Zoki Pharmaceutical Co., Ltd. | A method for promoting the synthesis of collagen and proteoglycan in chondrocytes |
CN103357006B (zh) * | 2012-10-10 | 2014-10-15 | 日本脏器制药株式会社 | 含有提取物的制剂的检查方法 |
JP5490939B2 (ja) * | 2013-04-19 | 2014-05-14 | 日本臓器製薬株式会社 | 抽出物及び製剤 |
WO2014178394A1 (ja) * | 2013-04-30 | 2014-11-06 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP5844320B2 (ja) * | 2013-08-23 | 2016-01-13 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
JP5844338B2 (ja) * | 2013-11-19 | 2016-01-13 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
EP3305307A4 (en) * | 2015-05-29 | 2019-02-20 | Nippon Zoki Pharmaceutical Co., Ltd. | PROMOTER OF MIGRATION OF PLURIPOTENT STEM CELLS |
JP6043922B2 (ja) * | 2015-11-20 | 2016-12-14 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
TWI705816B (zh) * | 2016-01-29 | 2020-10-01 | 國立大學法人千葉大學 | 用以製造肌損傷之預防或治療劑或修復促進劑之牛痘病毒接種炎症組織萃取物之用途 |
CN108738345A (zh) * | 2016-02-24 | 2018-11-02 | 国立大学法人大阪大学 | 试验方法 |
WO2018056412A1 (ja) | 2016-09-23 | 2018-03-29 | 国立大学法人大阪大学 | シュワン細胞分化促進剤及び末梢神経再生促進剤 |
JP2016216518A (ja) * | 2016-09-28 | 2016-12-22 | 日本臓器製薬株式会社 | 抽出物及び該抽出物を含有する製剤 |
US10376050B2 (en) * | 2017-12-22 | 2019-08-13 | Purpose Built, Inc. | Multi-functional kitchen device |
EP3918335A4 (en) * | 2019-01-30 | 2022-09-28 | Nippon Zoki Pharmaceutical Co., Ltd. | AGENTS FOR INHIBITING OR REDUCING INFLAMMATION IN THE BRAIN |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US616515A (en) * | 1898-12-27 | williams | ||
JPS53101515A (en) * | 1977-02-17 | 1978-09-05 | Nippon Zoki Pharmaceutical Co | Medicine having anodyne * sedative and antiallergic activity and production thereof |
JPS5587724A (en) * | 1978-12-27 | 1980-07-02 | Nippon Zoki Pharmaceut Co Ltd | Selective immune enhancer |
JPS6339572A (ja) | 1986-08-05 | 1988-02-20 | 株式会社チノー | 葉たばこ乾燥装置 |
JP2651674B2 (ja) * | 1987-07-23 | 1997-09-10 | 日本臓器製薬 株式会社 | 新規生理活性物質及びその製造方法 |
JPH0825885B2 (ja) * | 1988-04-15 | 1996-03-13 | 日本臓器製薬株式会社 | 特発性血小板減少性紫斑病治療剤 |
JP2539665B2 (ja) * | 1988-06-20 | 1996-10-02 | 日本臓器製薬株式会社 | 神経疾患治療剤 |
JP2539669B2 (ja) * | 1988-07-15 | 1996-10-02 | 日本臓器製薬株式会社 | 糖尿病性神経障害治療剤 |
JP2594222B2 (ja) | 1993-09-28 | 1997-03-26 | 日本臓器製薬株式会社 | 新規生理活性物質−kf |
CA2131574A1 (en) * | 1993-09-29 | 1995-03-30 | Mark A. Stiehl | Disposable holder for pre-filled cartridge-needle unit |
JP3852786B2 (ja) | 1995-04-25 | 2006-12-06 | 日本臓器製薬株式会社 | 骨萎縮改善剤 |
JP4033936B2 (ja) | 1997-01-08 | 2008-01-16 | 日本臓器製薬株式会社 | 一酸化窒素産生抑制剤 |
JPH1180005A (ja) | 1997-09-12 | 1999-03-23 | Nippon Zoki Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
JPH11139977A (ja) | 1997-11-07 | 1999-05-25 | Nippon Zoki Pharmaceut Co Ltd | Nef作用抑制剤 |
EP0953352A1 (en) * | 1998-04-27 | 1999-11-03 | Nippon Zoki Pharmaceutical Co., Ltd. | A therapeutic agent for ischemic diseases |
JP2000016942A (ja) | 1998-04-27 | 2000-01-18 | Nippon Zoki Pharmaceut Co Ltd | 虚血性疾患治療剤 |
CN1055249C (zh) * | 1998-07-15 | 2000-08-09 | 沈继平 | 一种镇痛药和其制造方法 |
KR20000076874A (ko) * | 1999-03-19 | 2000-12-26 | 고니시 진우에몬 | 케모카인 생산 촉진제 |
JP2000336034A (ja) | 1999-03-19 | 2000-12-05 | Nippon Zoki Pharmaceut Co Ltd | ケモカイン産生促進剤 |
JP4612924B2 (ja) * | 1999-08-20 | 2011-01-12 | 藤本製薬株式会社 | サイトカイン調節剤 |
PL361850A1 (en) | 2000-03-16 | 2004-10-04 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
US6521772B1 (en) * | 2001-09-27 | 2003-02-18 | Praxair Technology, Inc. | Synthesis of substituted ruthenocene complexes |
US6420583B1 (en) * | 2001-09-27 | 2002-07-16 | Praxair Technology, Inc | Methods of synthesizing ruthenium and osmium compounds |
AU2003275973A1 (en) * | 2002-06-12 | 2003-12-31 | Praxair Technology, Inc. | A method for producing organometallic compounds |
CN1207005C (zh) * | 2002-10-31 | 2005-06-22 | 威世药业(如皋)有限公司 | 含生物活性物质的兔皮和其用途 |
-
2003
- 2003-10-31 KR KR1020057007363A patent/KR101097138B1/ko active IP Right Grant
- 2003-10-31 CN CNB200380102599XA patent/CN100464782C/zh not_active Expired - Lifetime
- 2003-10-31 TW TW092130544A patent/TWI342778B/zh not_active IP Right Cessation
- 2003-10-31 CA CA2503810A patent/CA2503810C/en not_active Expired - Fee Related
- 2003-10-31 WO PCT/JP2003/013999 patent/WO2004039383A1/ja active Application Filing
- 2003-10-31 US US10/532,792 patent/US7148012B2/en not_active Expired - Lifetime
- 2003-10-31 AU AU2003280684A patent/AU2003280684B2/en not_active Ceased
- 2003-10-31 EP EP03770087.9A patent/EP1566178B1/en not_active Expired - Lifetime
- 2003-10-31 JP JP2004548103A patent/JP3887731B2/ja not_active Expired - Lifetime
-
2006
- 2006-07-28 US US11/494,637 patent/US7238487B2/en not_active Expired - Lifetime
-
2007
- 2007-05-24 US US11/802,742 patent/US7435547B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20070218037A1 (en) | 2007-09-20 |
US7148012B2 (en) | 2006-12-12 |
CN100464782C (zh) | 2009-03-04 |
CN1708311A (zh) | 2005-12-14 |
CA2503810A1 (en) | 2004-05-13 |
AU2003280684A1 (en) | 2004-05-25 |
EP1566178A1 (en) | 2005-08-24 |
JP3887731B2 (ja) | 2007-02-28 |
US7238487B2 (en) | 2007-07-03 |
AU2003280684B2 (en) | 2009-06-25 |
KR101097138B1 (ko) | 2011-12-22 |
TW200412983A (en) | 2004-08-01 |
EP1566178A4 (en) | 2006-09-06 |
JPWO2004039383A1 (ja) | 2006-02-23 |
CA2503810C (en) | 2012-03-13 |
US7435547B2 (en) | 2008-10-14 |
US20060263388A1 (en) | 2006-11-23 |
EP1566178B1 (en) | 2016-06-01 |
KR20050072457A (ko) | 2005-07-11 |
US20060051376A1 (en) | 2006-03-09 |
WO2004039383A1 (ja) | 2004-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI342778B (en) | Therapeutic agent for fibromyalgia | |
EP2191836A1 (en) | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent | |
AU2011225222B2 (en) | Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders | |
JP2004300146A (ja) | 感染防御剤 | |
US20230091957A1 (en) | Method for the Stimulation of Human Immune Cells | |
KR101331913B1 (ko) | 퇴행성 관절염에 대한 치료효과가 우수한 죽여 (竹茹)추출물 및 그를 포함하는 약제학적 조성물 | |
CN114949086B (zh) | 一种治疗脑出血的组合物 | |
WO2009086695A1 (zh) | 卡介菌多糖核酸提取物在制备治疗变态反应性皮肤病的药物中的应用及其注射剂和制备方法 | |
CN1846767A (zh) | 一种治疗腰间盘突出的中药丸剂 | |
JP7125732B2 (ja) | 神経因性膀胱の改善又は治療剤 | |
JP7125733B2 (ja) | 肢端紅痛症の改善又は治療剤 | |
SMITH | Men With HPV Found to Be at Greater HIV Risk | |
CN1270052A (zh) | 一种抗房劳、抗衰老的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4A | Expiration of patent term of an invention patent |